| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 9, 2025 4:30 P.M. |
| Form: | F-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 9, 2025 4:30 P.M. |
| Form: | F-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
6-K - PAINREFORM LTD. (0001801834) (Filer)
6-K - PAINREFORM LTD. (0001801834) (Filer)
6-K - PAINREFORM LTD. (0001801834) (Filer)
TEL AVIV, Israel, Dec. 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) today announced that its pharmaceutical division has completed an R&D assessment of LayerBio's proprietary drop-less, sustained-release ocular drug-delivery platform. The assessment confirmed that its sustained release, polymer matrix platform can incorporate a variety of drug entities, reinforcing its long-term potential to provide greatly improved pharmacological efficiency and simplify postoperative care for cataract patients by reducing or eliminating the need for medicated eye drops – the DROP-LESS advantage. The matrix platform successfully incorporated corticosteroids and NSAIDs—two major therapeutic
TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) today announced, through its pharmaceutical division, the commencement of its development plan for OcuRing™-K, LayerBio's patented, drop-less, intraoperatively administered sustained-release ocular therapy designed to deliver controlled, site-specific release of ketorolac following cataract surgery. Following the closing of PainReform's majority investment in LayerBio and the integration of OcuRing-K into PainReform's development portfolio, the Company conducted a methodical internal assessment with LayerBio's management team to define development priorities and establish a clear path for advancing the progra
TEL AVIV, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) today announced that DeepSolar, its solar energy business unit developing next-generation AI analytics, has advanced the development of its proprietary automated reporting engine, designed to transform how solar-asset performance is analyzed, understood, and communicated. The automated reporting engine reduces manual effort and produces tailored reports according to the customers' needs. Performance reports are essential tools for executive management, investors, and asset owners to assess a plant's operational and financial performance, identify the root causes of output variations, and evaluate return on
HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update. Significant events and achievements during the fourth quarter 2020 and subsequent period: Preparation for the first Phase 3 clinical trial, for patients undergoing bunionectomy surgery, is expected to begin by mid-2021Announced the engagement of Lotus Clinical Research as the Company’s clinical research organization to conduct the Phase 3 clinical trials under the leadership of Dr. Neil SinglaAnnounced the appointment of Ri
HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations. Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing
SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)
SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)
SC 13D/A - PAINREFORM LTD. (0001801834) (Subject)